Skip to main content

COVID 19 Updates from RheumNow

Hydroxychloroquine Fails as Pre-exposure Prophylaxis for COVID-19

Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs).  A new randomized controlled trial has shown that HCQ failed when

Young Adults are Driving Up COVID-19 Rates

CDC/MMWR

CDC reports that since June 2020 individuals infected with COVID-19 have largely been young adults in the 20-29 year age bracket.

Livedo, Purpura and Coagulopathy in Severe COVID-19

JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.

CDC Reverses Guidance for Asymptomatic COVID Contacts

Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.

RheumNow Podcast – Lupus Delights (9.18.20)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

COVID-19 Risks in Pregnant Women

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

RheumNow Podcast – To Celiac Test or Not? (9.4.20)

Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:

COVID and the Multisystem Inflammatory Syndrome in Children

Lancet Infectious Disease has reviewed the epidemiology, causes, clinical features, and current treatment for the multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19, noting severe organ damage can occur pediatric COVID-19 patients who are severely ill. 

CDC: COVID Seroprevalence in Health Care Workers

MMWR

CDC reports that gmong 3,248 healthcare personnel (HCP) observed, 6% had antibody evidence of previous SARS-CoV-2 infection; 29% of personnel with SARS-CoV-2 antibodies were asymptomatic in the preceding months, and 69% had not previously received a diagnosis of SARS-CoV-2 infection.

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.

Increased Lupus Anticoagulant Activity in COVID-19 Infection

JAMA Network Open reports that after adjusting for inflammation, lupus anticoagulant (LA) is significantly increased (positive) in COVID-19 patients and that LA positivity was associated with incidence risk of thrombotic events.

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

Dr. Jack Cush updates the news and joural articles from the past week on RheumNow.com

Social

To quash the virus, the immune system unleashes an arsenal. Sometimes these weapons turn inward and destroy healthy tissues. Combatting this friendly fire has become as crucial a part of the Covid-19 treatment strategy as subduing the virus itself. https://t.co/FrxVfSleEH

NYT Health NYTHealth( View Tweet)

3 weeks 3 days ago
https://t.co/0bh6Mh2pKP
Adam Cifu adamcifu( View Tweet)
3 weeks 4 days ago
Latest data Global Rheumatology Alliance COVID Registry -2121 pts (40% RA, 17% SLE, 9% PsA), 64% on DMARDs, 33% biologics, 5% JAKi, 34% steroid,27% HCQ, with only 7.6 deaths and 39% hospitalized and 81% resolved infection. https://t.co/g0w4QZHmRl

Dr. John Cush RheumNow( View Tweet)

4 weeks 1 day ago
Swiss cohort of 666 axSpA, RA & PsA pts seen before, during & after COVID; consults dropped 52%, remote visits increased 129%, & non-compliance slightly increased during COVID (axSpA 20% vs 13% before, p=0.003); but no incr in flares(<15%) or Dz activity https://t.co/lWb7WCwGbN

Dr. John Cush RheumNow( View Tweet)

4 weeks 1 day ago
The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more. Watch here>> https://t.co/cBHTeUQhff or liste to podcast here> https://t.co/KBgmsoGRzU or on iTunes> https://t.co/FHJv01AAbC

Dr. John Cush RheumNow( View Tweet)

1 month ago
As of 20 Sept, CDC reports total US COVID-19 deaths to be 198,754. In the last 7 days 281,490 new Cases. Trends flat averaging ~40,000 Cases per day and ~600-1100 deaths per day. https://t.co/CPLVhz6qeH

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Thank you all who participated in the survey. Here are some of our results #Covid_19 #rheumatology https://t.co/55ETf6kK6T

Bella Mehta bella_mehta( View Tweet)

1 month 1 week ago
The RheumNow podcast is up! Lupus delights - Lupus & Diet, Drug induced lupus & brand new biologics for SLE. Good news on immunosuppressives, colchicine and baricitinib in COVID-19 patients. . Watch it here https://t.co/Ymsd3eXN5d or listen to the podcast https://t.co/20FOr3qu3X

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Retrospective cohort study of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater risk of hospitalized or ventilation and immunosuppressive use was not shown to worsened the course of disease (TNFi decreased risk of hospitalization) https://t.co/gmIXDJkLCt

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
Baricitinib in combo with Remdesivir reduces time to recovery in COVID-19 hospitalized pts in NIH-run ACTT-2 Trial w/ >1000 pts randomized to recv 4-mg baricitinib plus remdesivir versus remdesivir alone. Other baricitinib-COVID trials are in progress https://t.co/J87Ypeb4mn

Dr. John Cush RheumNow( View Tweet)

1 month 2 weeks ago
×